Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Abeona Therapeutics Inc.

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Provides Regulatory Update on Pz-cel
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces $50 Million Credit Facility
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
From Abeona Therapeutics Inc.
Via GlobeNewswire
Tickers ABEO
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.